![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Hear from our experts on how smarter scheduling and technology strengthen patient experience in health system infusion centers.
MHS In the News: Transparency in Drug Pricing Can Start with 340B
Key considerations in understanding 340B program results and benefits.
By
Date
July 13, 2021
Read time: less than 1 minute
A lack of transparency across the pharmacy marketplace stems from a number of different factors. Ultimately, it impacts the patient experience and can create confusion.
Heightened transparency across the broader system could help support health systems’ ability to generate savings and revenue to support extending care to the uninsured and underinsured, which is key to extending pharmacy and patient care services.
Andrew Wilson, vice president, 340B Solutions for McKesson, shares three key considerations in understanding 340B program results and benefits. Read more from Drug Topics.
Related Stories
The most downloaded content by health system pharmacy leaders in December 2025.
This interactive checklist guides you through 10 critical questions that can help uncover next steps for your health system’s specialty pharmacy strategy.
Get to know one of our McKesson Health Systems pharmacy experts and industry-leading voices, Rafael Saenz.
Hospital leaders discuss ambulatory pharmacy strategies, 340B considerations, and value-based care optimization at McKesson's Becker's Roundtable session.
The most downloaded content by health system pharmacy leaders in November 2025.
Take a look at the industry insights, experience, and expertise you’ll have access to at this year’s ASHP Midyear.
Do you know where your health system infusion patients are going – and, more importantly, why?
Answering these questions can help differentiate transactional vendor relationships from strategic partnerships that add value.
The most downloaded content by health system pharmacy leaders in October 2025.